CDK4/6 Inhibitor
Abemaciclib for Neurofibroma
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing a drug, abemaciclib, to see if it can help treat atypical neurofibromas, which are tumors that arise from nerves and can cause serious medical problems. The drug is taken orally, twice daily, in 28-day cycles.
Antioxidant
Antioxidant Therapy for Neurofibromatosis Type 1
Recruiting0 awardsPhase 2
Cincinnati, Ohio
This trial is testing a medication called NAC in children aged 8-16 with a condition called NF1. These children often have problems with movement and behavior, and there is no current treatment for these issues. NAC works by reducing harmful molecules in the brain, which may help improve these symptoms.
Antioxidant
Antioxidant Therapy with N-acetylcysteine for Neurofibromatosis Type 1
Recruiting0 awardsPhase 2
Cincinnati, Ohio
This trial tests N-Acetyl Cysteine (NAC), a common supplement, to see if it can help children with neurofibromatosis type 1 (NF1) who have cognitive, behavioral, and motor issues. NAC works by reducing harmful substances in the brain, potentially improving behavior and motor skills. NAC is a precursor to glutathione (GSH) and has been studied for its neuroprotective and cognitive benefits in various conditions.
Kinase Inhibitor
Dabrafenib + Trametinib + Hydroxychloroquine for Brain Tumor
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial is designed to study the side effects and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with brain tumors that have progressed or returned while receiving a similar agent.
Kinase Inhibitor
Dabrafenib + Trametinib for Brain Tumors
Recruiting3 awardsPhase 4
Phoenix, Arizona
This trial is studying the effects of two cancer medications, dabrafenib and trametinib, in children. These drugs work by stopping signals that make cancer cells grow. Dabrafenib and trametinib have shown benefits in various BRAF-mutant tumors, including melanoma, lung cancer, and thyroid cancer. The goal is to see how these treatments affect children over time.
MEK Inhibitor
MEK Inhibitor for Neurofibromatosis
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial tests mirdametinib, a medication taken by mouth, for patients with NF1-related tumors that can't be surgically removed. The drug works by blocking specific proteins to stop or shrink the tumors. Mirdametinib has shown significant and lasting decreases in pain and partial responses in NF1-related plexiform neurofibromas.
Popular Filters
Trials for NF Patients
MEK Inhibitor
Trametinib for Juvenile Myelomonocytic Leukemia
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial looks at how well trametinib works in treating patients with JML who have relapsed or who don't respond to treatment. Trametinib may stop tumor cell growth by blocking enzymes needed for cell growth.
Aspirin for Acoustic Neuroma
Recruiting0 awardsPhase 2
Stanford, California
This trial is testing whether aspirin can slow tumor growth and improve hearing in patients aged 12+ with vestibular schwannomas. Aspirin's anti-inflammatory properties might help achieve these effects. Aspirin has been studied for its potential to protect against certain types of hearing loss and has shown some protective effects in previous studies.
Behavioral Intervention
Medication + Reading Tutoring for Learning Disabilities in Neurofibromatosis Type 1
Recruiting0 awardsPhase 2
Nashville, Tennessee
This trial will study whether the combination of a medication and reading tutoring can help improve learning disabilities in children with Neurofibromatosis Type 1.
Photosensitizer
Photodynamic Therapy for Neurofibromatosis
Recruiting1 awardPhase 2
Milwaukee, Wisconsin
This trial is testing a new treatment for neurofibromas in patients with NF1. The treatment involves using a light-activated drug (Levulan Kerastick) and red light to kill the neurofibromas. The investigators will measure how well the treatment works and how long it works for.
Trials for Neurofibroma Patients
MEK Inhibitor
Trametinib for Juvenile Myelomonocytic Leukemia
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial looks at how well trametinib works in treating patients with JML who have relapsed or who don't respond to treatment. Trametinib may stop tumor cell growth by blocking enzymes needed for cell growth.
Aspirin for Acoustic Neuroma
Recruiting0 awardsPhase 2
Stanford, California
This trial is testing whether aspirin can slow tumor growth and improve hearing in patients aged 12+ with vestibular schwannomas. Aspirin's anti-inflammatory properties might help achieve these effects. Aspirin has been studied for its potential to protect against certain types of hearing loss and has shown some protective effects in previous studies.
Behavioral Intervention
Medication + Reading Tutoring for Learning Disabilities in Neurofibromatosis Type 1
Recruiting0 awardsPhase 2
Nashville, Tennessee
This trial will study whether the combination of a medication and reading tutoring can help improve learning disabilities in children with Neurofibromatosis Type 1.
Photosensitizer
Photodynamic Therapy for Neurofibromatosis
Recruiting1 awardPhase 2
Milwaukee, Wisconsin
This trial is testing a new treatment for neurofibromas in patients with NF1. The treatment involves using a light-activated drug (Levulan Kerastick) and red light to kill the neurofibromas. The investigators will measure how well the treatment works and how long it works for.
Trials for NF1 Positive Patients
Behavioral Intervention
Medication + Reading Tutoring for Learning Disabilities in Neurofibromatosis Type 1
Recruiting0 awardsPhase 2
Nashville, Tennessee
This trial will study whether the combination of a medication and reading tutoring can help improve learning disabilities in children with Neurofibromatosis Type 1.
Photosensitizer
Photodynamic Therapy for Neurofibromatosis
Recruiting1 awardPhase 2
Milwaukee, Wisconsin
This trial is testing a new treatment for neurofibromas in patients with NF1. The treatment involves using a light-activated drug (Levulan Kerastick) and red light to kill the neurofibromas. The investigators will measure how well the treatment works and how long it works for.
Kinase Inhibitor
Selumetinib for Pediatric Brain Cancer
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing a new drug to treat young patients with brain cancer that has come back or does not respond to treatment. The drug may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Procedure
AI-Enhanced MRI for Detecting Precancerous Lesions in Neurofibromatosis
Recruiting1 award2 criteria
Los Angeles, California
This trial uses a full-body scan and smart computer software to monitor changes in pediatric patients with neurofibromatosis type 1. The MRI takes detailed images, and the AI analyzes them to track any changes over time.
Trials With No Placebo
Mitogen-activated Protein Kinase (MAPK) Inhibitor
Trametinib for Pediatric Brain Tumor
Recruiting1 awardPhase 2
Calgary, Alberta
This trial will study the response rate of pediatric brain tumors to oral administration of the drug trametinib. A total of 150 patients will be recruited, and the study will also explore the molecular mechanisms behind tumor development, progression and resistance to treatment.
MEK Inhibitor
Trametinib for Juvenile Myelomonocytic Leukemia
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial looks at how well trametinib works in treating patients with JML who have relapsed or who don't respond to treatment. Trametinib may stop tumor cell growth by blocking enzymes needed for cell growth.
Photosensitizer
Photodynamic Therapy for Neurofibromatosis
Recruiting1 awardPhase 2
Milwaukee, Wisconsin
This trial is testing a new treatment for neurofibromas in patients with NF1. The treatment involves using a light-activated drug (Levulan Kerastick) and red light to kill the neurofibromas. The investigators will measure how well the treatment works and how long it works for.
Kinase Inhibitor
Turalio for Leukemia
Recruiting1 awardPhase 1
Bethesda, Maryland
This trial is testing a drug called PLX3397 to see if it can help treat certain types of cancer. Eligible participants will take the drug once daily for a 28-day cycle, and will have various tests and procedures throughout the study.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.